LONDON, UK, 4 March 2025 - In a comprehensive Genomic Press Viewpoint (review) article, researchers are shining a spotlight on a revolutionary approach to tackling neuroendocrine tumours (NETs), a ...
Aug. 30, 2023 8:17 AM ETPerspective Therapeutics, Inc. (CATX) Title: Targeted Alpha Therapy for Neuroendocrine Tumors: Therapeutic Efficacy and Dosimetry Analysis of [212 Pb]VMT-α-NET in Preclinical ...
BEDFORD, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (LNTH) (Lantheus) today announced it has entered into multiple strategic agreements with Perspective Therapeutics, Inc.
[212 Pb]VMT-α-NET shows promise in effectively treating neuroendocrine tumors Administration of fractionated doses of [212 Pb]VMT-α-NET shows 100% survival in a robust model of metastatic ...
The grant from the Medical Research Council (MRC) of the United Kingdom (part of UK Innovation and Research; UKRI) is supporting preclinical in vitro and in vivo studies of [212 Pb]VMT-α-NET for ...
Drs. Kalyan M. Shekhda1 (Royal Free Hospital, London, UK), Shaunak Navalkissoor Royal Free Hospital, London, UK), and Ashley B. Grossman (University of Oxford and Queen Mary University of London, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results